- Home
- VRTS vs XERS Comparison
VRTS vs XERS Comparison
Compare VRTS & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VRTS | XERS |
|---|---|---|
| Founded | 1988 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 968.0M | 1.0B |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VRTS | XERS |
|---|---|---|
| Price | $135.18 | $5.85 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $158.00 | $10.83 |
| AVG Volume (30 Days) | 69.3K | ★ 1.6M |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.68% | N/A |
| EPS Growth | 18.24 | ★ 100.00 |
| EPS | ★ 1.05 | 0.01 |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | N/A | $34.37 |
| Revenue Next Year | $1.66 | $22.86 |
| P/E Ratio | ★ $133.01 | $601.00 |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $121.61 | $4.30 |
| 52 Week High | $214.88 | $10.08 |
Technical Indicators
Market Signals| Indicator | VRTS | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 40.38 | 43.01 |
| Support Level | $124.44 | $5.79 |
| Resistance Level | $147.15 | $7.14 |
| Average True Range (ATR) | 6.42 | 0.30 |
| MACD | -0.97 | -0.04 |
| Stochastic Oscillator | 29.20 | 5.96 |
Price Performance
Historical ComparisonAbout VRTS Virtus Investment Partners Inc.
Virtus Investment Partners Inc provides investment management and related services to institutions and individuals. It uses a multi-manager, multi-style approach, offering investment strategies from investment managers, each having its distinct investment style, autonomous investment process, and individual brand, as well as from select unaffiliated managers for certain funds. Through its multi-manager model, the group provides investment managers with distribution, business, and operational support. The Company operates in one business segment, namely as an asset manager providing investment management and related services for individual and institutional clients.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.